19 Analysts Have This To Say About Sage Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 19 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), with opinions ranging from bullish to bearish. The average 12-month price target has decreased by 22.32% to $19.63. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance.
June 20, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have provided mixed ratings for Sage Therapeutics, with a notable decrease in the average 12-month price target by 22.32% to $19.63. This reflects a shift in sentiment and expectations for the company's future performance.
The decrease in the average price target and the mixed ratings from analysts indicate a less optimistic outlook for Sage Therapeutics. This could lead to a short-term decline in the stock price as investors react to the lowered expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100